An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
Ascletis, a biopharma company, reported early clinical results for a new pill called ASC30 that targets diabetes. In a Phase II trial, people with type 2 diabetes who took the drug saw reductions in their HbA1c levels (a common measure of long-term blood sugar) of up to 1.7 percentage points. The announcement is preliminary — it’s encouraging but not the final word, because Phase II tests are meant to check effectiveness and safety in a modest-sized group before larger trials. ASC30 is described as an oral GLP-1. That means it’s a pill designed to act like GLP-1, a natural hormone your gut makes after you eat. GLP-1 helps lower blood sugar by prompting the pancreas to release insulin after meals, slowing how fast your stomach empties, and reducing appetite. Right now, most GLP-1 medicines (like Ozempic and Wegovy) are injections. The idea of ASC30 is to give the same kind of effect in a tablet you swallow. The report says the drug lowered HbA1c by up to 1.7 percentage points in this Phase II study. HbA1c reflects average blood sugar over a few months, so a drop of that size would be clinically meaningful if confirmed. However, the announcement doesn’t say how many people were in the trial, how long it lasted, or how consistent the results were across participants. Phase II trials often involve dozens to a few hundred people, not the thousands seen in final approval studies, so the result is promising but needs confirmation in larger, longer trials. This matters because many people with type 2 diabetes need better, easier treatments. An effective oral GLP-1 could be a big convenience win compared with injectable versions. It could also expand access for people who are reluctant or unable to use injections. If the effect holds up in later trials and safety is good, a pill that reduces HbA1c substantially could become another option for clinicians treating diabetes. There are important caveats. Early-phase trial results can overstate benefits that shrink or disappear in larger studies. The company’s announcement likely highlights the best outcomes; we don’t have details here about side effects, who was excluded from the trial, or whether the drug worked equally well for different groups. GLP-1 drugs can cause nausea, vomiting, or gastrointestinal upset, and they have other safety questions that regulators watch closely. ASC30’s regulatory status isn’t established — it’s not an approved drug yet. Bottom line: Ascletis’ pill-like GLP-1 showed promising HbA1c drops in a Phase II study, but we need larger, detailed trials and safety data before knowing whether it will be a reliable, widely available diabetes treatment.
Source: BioPharma APAC